ClinicalTrials.gg
RecruitingNCT07189169Updated Sep 23, 2025

QA108 Phase III Study in Subjects With Intermediate AMD

A Phase 3 interventional study of QA108 granules and QA108 granules placebo in Intermediate Age-Related Macular Degeneration, sponsored by Smilebiotek Zhuhai Limited. Recruiting at 1 site in China. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Smilebiotek Zhuhai Limited · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
13th of 91
400 · median 62
Started
2025
with 14 others
Phase 3
18 of 107
4 open now
Primary completion
2027-03
later than 27 of 42 live
Registered
93rd of 107
by date

Among the 107 studies in Macular Degeneration with a site in China, this one is the 13th largest by planned enrollment of the 91 interventional ones that give a count, is one of 15 that started in 2025, is one of 18 in phase 3, reaches primary completion later than 27 of the 42 other live ones, and was the 93rd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

03

Conditions studied

  • Intermediate Age-Related Macular Degeneration
04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The study eye meets the Western medicine diagnostic criteria for intermediate age-related macular degeneration;
  2. Presence of at least one large drusen (diameter ≥125 μm) in the macular area of the fundus;
  3. Consistent with the TCM diagnosis of type of Yang-hyperactivity due to Yin-deficiency;
  4. Age 45-85 years (inclusive), regardless of gender;
  5. The study eye has a BCVA of 88-34 letters (using the ETDRS chart, inclusive of threshold values), equivalent to a Snellen visual acuity of 20/20 to 20/200 (inclusive);
  6. Voluntary participation in this clinical trial, with provided and an informed consent form signed

Exclusion criteria

Exclusion Criteria:

  1. The study eye is with concomitant eye disorders that may interfere with the observation of the trial as judged by the investigator, including pathological myopia, glaucoma, diabetic retinopathy, retinal vein occlusion, uveitis, retinal detachment, optic neuropathy (optic neuritis, atrophy, papilledema), and macular hole;
  2. The study eye has an intraocular pressure (IOP) ≥ 25 mmHg;
  3. Presence of geographic atrophy (GA) involving the foveal center in the study eye;
  4. Previous ophthalmic surgery in the study eye: vitrectomy, macular translocation;
  5. Aphakia (except pseudophakia) or posterior capsule rupture (except YAG laser posterior capsulotomy after IOL implantation at more than 1 month prior to screening) of the study eye;
  6. Any intraocular surgery (excluding intravitreal injections) that may affect trial observations or imaging in the study eye within 3 months;
  7. Cataract in the study eye that interferes with fundus examination or imaging;
  8. Treatments received in the study eye within 3 months prior to screening, including macular laser photocoagulation and micropulse laser therapy;
  9. The patient received relevant TCM treatment within 1 month prior to screening;
  10. Active ocular infection in either eye that affects fundus examination or imaging;
  11. The non-study eye has a BCVA of less than 19 ETDRS letters (not inclusive);
  12. Known allergy to the therapeutic or diagnostic drug used in the study protocol, including the single drug components in the study drugs;
  13. Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg after regular use of antihypertensive drugs);
  14. count ≤100×10⁹/L (unless follow-up results are normal), or any of the following exceeding 1.5 times the (ULN): total (TBIL), (ALT), aspartate aminotransferase (AST), or serum creatinine (Cr);
  15. Pregnant women, women who are breastfeeding, those who plan for pregnancy in the next six months, or those who are unwilling to take effective birth controls during the study course and until six months after drug withdrawal;
  16. Any uncontrollable clinical disorder prior to the start of treatment, such as severe psychiatric, neurological, respiratory, immunological, hematological, and cardiac system diseases, and malignant tumors;
  17. Subjects who have participated in other clinical trials within 3 months prior to this trial;
  18. Patients who are unsuitable for participating at the discretion of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    QA108 granules, 7.5 g/bag,2 bags/time, BID

    Drug: QA108 granules

  • Placebo comparator
    QA108 granule simulants, 7.5 g/bag,2 bags/time, BID

    Drug: QA108 granules placebo

Interventions

  • DrugQA108 granules

    Take the medication as required for 24 weeks

  • DrugQA108 granules placebo

    Take the medication as required for 24 weeks

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in drusen area

    Time frame: weeks 24

Secondary outcomes

  1. Percentage change from baseline in drusen area

    Time frame: weeks 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 19 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2025
First posted
Sep 23, 2025
StartActual
Jul 8, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 30, 2027
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07189169
Lead sponsor
Smilebiotek Zhuhai Limited
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Jul 8, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

Hong Dai
Contact
Dai-hong@x263.net
010-85132171

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion